Sensei Biotherapeutics (SNSE) is now covered by Leerink Partners. They set an "outperform" rating and a $50.00 price target on the stock.
Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)